Neue Substanzen in der Therapie von Kopf-Hals-Tumoren

Zusammenfassung

In den letzten 3 Jahren wurden mehrere neue Medikamente zur Tumortherapie von der amerikanischen Arzneimittelbehörde (FDA) zugelassen. Es werden für die HNO-Heilkunde interessante Neuzulassungen vorgestellt und erläutert. Diese neuen Therapieformen haben in Deutschland bereits Einzug in die Therapie von Kopf-Hals-Tumoren gehalten oder werden dies in den nächsten Jahren voraussichtlich tun.

New Substances in the Therapy of Head and Neck Cancer

During the last 3 years the FDA approved numerous innovative drugs for cancer therapy. Drugs relevant to the otolaryngologist are presented and discussed. These new therapeutic tools may play a future part also in the therapy of head and neck cancer.

Erlotinib - Gefitinib - Cetuximab - Imiquimod - Palifermin - Tositumomab - Bevacizumab - HNO-Tumore - Antikörper - neue Tumortherapien

Erlotinib - Gefitinib - Cetuximab - Imiquimod - Palifermin - Tositumomab - Bevacizumab - head and neck tumors - antibodies - new tumor therapies

Literatur

• 1 Stockfleth E, Sterry W. New treatment modalities for basal cell carcinoma.  Recent Results Cancer Res. 2002;  160 259-268
• 2 Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview.  Br J Dermatol. 2003 Nov;  149 (Suppl 66) 53-56
• 3 . http://www.cancer.gov/clinicaltrials/developments/newly-approved-treatments/page3
• 4 Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy.  Signal. 2000;  1 12-21
• 5 Nicholson R I, Gee J M, Harper M E. EGFR and cancer prognosis.  Eur J Cancer. 2001;  37 (Suppl 4) 9-15
• 6 Lee J W, Soung Y H, Kim S Y, Nam H K, Park W S, Nam S W, Kim M S, Sun D I, Lee Y S, Jang J J, Lee J Y, Yoo N J, Lee S H. Somatic mutations of EGFR gene in squamos cell carcinoma of the head and neck.  Clin Cancer Res. 2005;  11 (8) 2879-2882
• 7 Stanton P, Richards S, Reeves J, Nikolic M, Edington K, Clark L. Epidermal growth factor receptor expression by human squamos cell carcinomas of the head and neck, cell lines and xenografts.  Br J Cancer. 1994;  70 427-433
• 8 . http://www.cancer.gov/clinicaltrials/developments/newly-approved-treatments/page24
• 9 Cohen M H, Johnson J R, Chen Y F, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (tarceva®) tablets.  Oncologist. 2005;  10 (7) 461-466
• 10 Caponigro F, Ionna F, Comella G. New cytotoxic and molecular-targeted therapies of head and neck tumors.  Curr Opin Oncol. 2004;  16 (3) 225-230
• 11 . http://www.cancer.gov/clinicaltrials/results/head-neck-cetuximab0604
• 12 Buske C, Dreyling M, Unterhalt M, Hiddemann W. Monoclonal antibody therapy for malignant lymphoma.  Med Klin (Munich). 2005;  100 (1) 14-24
• 13 Horning S J, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M. Efficiacy and safety of tositumomab and iodine-131 tositumomab (Bexxar®) in B-cell lymphoma, progressive after rituximab.  J Clin Oncol. 2005;  23 (4) 712-719
• 14 .http://www.cancer.gov/clinicaltrials/developments/newly-approved-treatments/page8
• 15 Clarkson J. Palifermin improves oral mucositis after high dose chemotherapy and radiotherapy plus stem cell transplantation in people with haematological cancers.  Cancer Treat Rev. 2005 Aug 18;  [Epub ahead of print]
• 16 .http://www.cancer.gov/clinicaltrials/developments/newly-approved-treatments/page21
• 17 .http://www.fda.gov/cder/drug/infopage/palifermin/paliferminQA.htm
• 18 .http://www.cancer.gov/clinicaltrials/developments/newly-approved-treatments/page9